Long­board stock soars on heels of pos­i­tive topline da­ta for seizure med­ica­tion

Long­board Phar­ma­ceu­ti­cals’ stock $LBPH sky­rock­et­ed by more than 200% Tues­day af­ter the com­pa­ny re­leased topline da­ta from its study for an oral drug to treat seizures as­so­ci­at­ed with de­vel­op­men­tal and epilep­tic en­cephalopathies.

Long­board pub­lished ini­tial re­sults from Phase Ib/IIa of the com­pa­ny’s PA­CIF­IC study, which is eval­u­at­ing bex­i­cas­erin, a 5-HT2C re­cep­tor su­per­ag­o­nist. The study looked at 52 peo­ple aged 12 to 65 with DEE in the US and Aus­tralia and demon­strat­ed a 53% seizure re­duc­tion com­pared to about 21% in the place­bo group.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER